Loading
Life sciences · Journal article
Medicina · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Intragastric balloons (IGBs) were developed to bridge the gap between lifestyle intervention and Metabolic and Bariatric Surgery (MBS), but the advent of highly efficacious pharmacotherapies and Endoscopic Sleeve Gastroplasty (ESG) has challenged their role. This narrative review synthesises contemporary evidence and guideline recommendations regarding IGBs, focusing on short-term efficacy, durability, safety, psychological aspects, and health system considerations in comparison with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), dual GIP (Glucose-dependent Insulinotropic Polypeptide)/GLP-1 RAs, ESG, and MBS. Across randomised trials and meta-analyses, IGBs consistently produce modest short-term weight loss of approximately 10–15% total body weight at six months, with frequent weight regain following removal and limited long-term benefit. In contrast, modern pharmacotherapy achieves greater and more durable weight loss with fewer procedural risks. Current guidelines therefore position IGBs as adjunctive or bridging interventions reserved for selected patient subgroups, rather than as a dominant intermediate therapy. Overall, current evidence supports a selective role for IGBs as bridging, adjunctive, or combination interventions within multimodal obesity pathways, particularly for patients who cannot access or tolerate pharmacotherapy or who require a behavioural and metabolic bridge to surgery.